newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

JBIO
  • Jade Biosciences announced positive interim Phase 1 results for JADE101 in IgA nephropathy, showing ~70% IgA reduction after a single 700 mg dose & potential for every 12-week subcutaneous dosing.
  • The Phase 2 JUNIPER trial for JADE101 is underway with interim data expected in 2027, while a Phase 3 registrational trial is planned for the first half of 2027.
  • Dosing began for JADE201 in a Phase 1 rheumatoid arthritis trial, with interim biomarker data anticipated in 2027.
  • JADE301, a half-life-extended anti-IFN-β for dermatomyositis, is scheduled to begin a Phase 1 healthy volunteer trial in Q4 2026 with interim data expected in H2 2027.
  • The company completed a $172.5 million public offering, resulting in $461.2 million in cash, cash equivalents, & investments as of June 30, 2026, providing a runway into Q4 2028.
  • Mark Eisner, M.D., M.P.H., was appointed to the Jade Board of Directors.
  • Second quarter 2026 R&D expenses totaled $50.1 million, while G&A expenses were $8.9 million.
  • Net loss for the quarter ended June 30, 2026, was $55.8 million, compared to $32.1 million in the same period last year.
  • As of June 30, 2026, Jade had approximately 83.9 million shares of common stock & common stock equivalents outstanding.